Inspire Pharmaceuticals Inc

Inspire Pharmaceuticals — CEUT Emerging Growth Conference 2007

26 slides from Inspire Pharmaceuticals's conference presentation, Jul 11, 2007

  1. Slide 1: CEUT Emerging Growth Conference

    CEUT EMERGING GROWTH CONFERENCE July 11, 2007 CEUT EMERGING CEUT EMERGING GROWTH CONFERENCE GROWTH CONFERENCE July 11, 2007 July 11, 2007 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements Forward-Looking Statements This presentation contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995 which convey management's expectations, beliefs, plans and objectives regarding future performance. These statements discus

  3. Slide 3: Inspire: An Integrated Company With a Therapeutic Focus

    3 Inspire: An Integrated Company With a Therapeutic Focus Inspire: An Integrated Company With a Therapeutic Focus Vertically-integrated with R&D and commercial capabilities Therapeutic focus in ophthalmology & respiratory/ allergy Specialized sales force generating attractive revenue stream Robust p

  4. Slide 4: Inspire's Balanced and Growing Portfolio

    4 Inspire’s Balanced and Growing Portfolio Elestat ® for allergic conjunctivitis Restasis ® for dry eye Glaucoma Prolacria ™ for dry eye AzaSite ™ for bacterial conjunctivitis Inspire’s Balanced and Growing Portfolio Approved NDA Filed Phase 3 Phase 2 Phase 1 Bilastine Oral for allergic rhinitis (AR

  5. Slide 5: Attractive Stream of Revenues

    5 Attractive Stream of Revenues Attractive Stream of Revenues $23 mm $45 - 57 mm* Inspire Annual Revenues $11 mm Elestat ® Restasis ® *Guidance provided on 5/9/07 $37 mm $76 million cash & investments balance, as of 3/31/07 $40 million debt 2007 Guidance* Aggregate revenue of $45 to $57 million Oper

  6. Slide 6: Ophthalmic Products and Pipeline Programs

    6 Ophthalmic Products and Pipeline Programs Ophthalmic Products and Pipeline Programs

  7. Slide 7: Commercial Infrastructure Leveraged With Three Products

    7 Commercial Infrastructure Leveraged With Three Products Commercial Infrastructure Leveraged With Three Products

  8. Slide 8: Differentiated Product for Bacterial Conjunctivitis

    8 Differentiated Product for Bacterial Conjunctivitis Differentiated Product for Bacterial Conjunctivitis Approved by FDA on April 27, 2007 Launch expected in mid-August 2007 Licensed Feb. 2007 from InSite Vision Well-known broad spectrum antibiotic Convenient dosing regimen Approved for patients on

  9. Slide 9: Reduced Dosing Regimen Compared to Other Products

    9 Day 5 Day 4 Day 7 Day 6 Day 3 Day 2 Day 1 Day 5 Day 4 Day 7 Day 6 Day 3 Day 2 Day 1 Reduced Dosing Regimen Compared to Other Products Reduced Dosing Regimen Compared to Other Products AzaSite ™ – 9 drops per affected eye Current market leader – 21 drops per affected eye

  10. Slide 10: Attractive Bacterial Conjunctivitis Market

    10 Attractive Bacterial Conjunctivitis Market Attractive Bacterial Conjunctivitis Market *Market share based on single-entity products for the 12 months ended 12/31/06; Source: IMS **Guidance provided on April 27, 2007 $362 million annual U.S. prescription sales* AzaSite ™ 2008 Target Sales of $30 –

  11. Slide 11: Current Market Provides Targeting Opportunities

    11 Current Market Provides Targeting Opportunities Current Market Provides Targeting Opportunities *Data based on single-entity products for the 12 months ended 12/31/06; Source: IMS 15 million U.S. ophthalmic anti-infective prescriptions in 2006* Inspire’s sales force will target top prescribers wr

  12. Slide 12: Elestat - Competitive Allergic Conjunctivitis Product

    12 Elestat ® - Competitive Allergic Conjunctivitis Product Elestat ® - Competitive Allergic Conjunctivitis Product Prevents ocular allergy symptoms by Blocking H and H receptors Stabilizing mast cells Stopping progression of pro-inflammatory mediators Important features Low affinity for M Soothing u

  13. Slide 13: Large and Growing Allergic Conjunctivitis Market

    13 Large and Growing Allergic Conjunctivitis Market Large and Growing Allergic Conjunctivitis Market $476 million annual U.S. prescription sales* 45% of total prescriptions are written by eye care and allergy specialists* *12 months ended 12/31/06; Source: IMS Patanol® Elestat® Optivar® Zaditor® & G

  14. Slide 14: Dry Eye Affects 30 Million Patients in Major Markets

    14 Dry Eye Affects 30 Million Patients in Major Markets Signs/Symptoms Treatments Causes Dry Eye Affects 30 Million Patients in Major Markets Corneal damage Foreign body sensation Persistent irritation/redness Light sensitivity Pain/burning Impaired vision Signs/Symptoms Limited treatment options Re

  15. Slide 15: Strong and Continued Growth of Restasis

    15 Strong and Continued Growth of Restasis ® Strong and Continued Growth of Restasis ® * Allergan estimate (5/2/07) $100 mm $270 mm $320 - 340 mm Total Global Sales of Restasis as Reported by Allergan $38 mm $191 mm 2003 2004 2005 2006 2007 est*

  16. Slide 16: Prolacria - A Unique Mechanism of Action for Dry Eye

    16 Prolacria ™ – A Unique Mechanism of Action for Dry Eye Prolacria ™ – A Unique Mechanism of Action for Dry Eye Internally-developed P2Y agonist Promotes release of components of natural tear-film (fluid, mucin and lipids) Good tolerability and safety profile Excellent proprietary position Two appr

  17. Slide 17: Novel Glaucoma Program

    17 Novel Glaucoma Program Novel Glaucoma Program Leading cause of preventable blindness in U.S. Largest market in ophthalmic pharmaceuticals - $1.7 billion in annual prescription sales* Unique technology platform licensed from Wisconsin Alumni Research Foundation Novel approach to lowering IOP by ta

  18. Slide 18: Respiratory/Allergy Pipeline Programs

    18 Respiratory/Allergy Pipeline Programs Respiratory/Allergy Pipeline Programs

  19. Slide 19: Cystic Fibrosis: Life Threatening, Genetic Disease

    19 Cystic Fibrosis: Life Threatening, Genetic Disease Cystic Fibrosis: Life Threatening, Genetic Disease Snapshot of CF’s Impact: ~ 30,000 U.S. patients; 75,000 worldwide Life expectancy: ~ 37 yrs 90% of CF patients die of respiratory failure Two-third’s of CF patients have mild disease 60% of CF po

  20. Slide 20: Phase 3 Program: Denufosol is an Early Intervention Approach

    20 Phase 3 Program: Denufosol is an Early Intervention Approach Phase 3 Program: Denufosol is an Early Intervention Approach Phase 3 program focused on early intervention for patients with mild lung disease Two Phase 3 clinical efficacy trials planned First trial, TIGER - 1 , ongoing in U.S. - Enrol

  21. Slide 21: High Prevalence of Allergic Rhinitis

    21 High Prevalence of Allergic Rhinitis High Prevalence of Allergic Rhinitis 40 million people in U.S. suffer from allergic rhinitis th leading cause of chronic disease in U.S. 17 million office visits per year Annual cost of allergy disease estimated at $7 billion *Sources: American Academy of Alle

  22. Slide 22: Bilastine - Antihistamine Licensed from FAES FARMA

    22 Bilastine – Antihistamine Licensed from FAES FARMA Bilastine – Antihistamine Licensed from FAES FARMA Licensed U.S./ Canadian rights for bilastine from FAES in 2006 Once-daily, oral, highly selective H -antihistamine Composition of matter patent through 2017 Two large positive Phase 3 comparative

  23. Slide 23: Epinastine Nasal Spray: Advancing to Phase 3

    23 Epinastine Nasal Spray: Advancing to Phase 3 Licensed U.S./ Canadian rights for epinastine nasal spray for rhinitis from Boehringer Ingelheim in 2006 Positive results in Phase 2 trial 14-day trial in 569 subjects in mountain cedar pollen season Met primary endpoint of reflective total nasal sympt

  24. Slide 24: Attractive Market for Nasal Treatment of Allergic Rhinitis

    24 Attractive Market for Nasal Treatment of Allergic Rhinitis Attractive Market for Nasal Treatment of Allergic Rhinitis $2.7 billion annual U.S. prescription sales* * Information is for 12 months ended 12/31/06; Source: IMS ** Source: American Academy of Allergy, Asthma & Immunology million patient

  25. Slide 25: Key Milestone and Catalysts in 2007

    25 Key Milestone and Catalysts in 2007 In-licensed and received FDA approval of AzaSite Reported positive results in Phase 2 epinastine nasal spray mountain cedar trial Met with FDA regarding next steps for oral bilastine - Amended FAES agreement Met with FDA regarding next steps for epinastine nasa

  26. Slide 26: CEUT Emerging Growth Conference

    CEUT EMERGING GROWTH CONFERENCE July 11, 2007 CEUT EMERGING CEUT EMERGING GROWTH CONFERENCE GROWTH CONFERENCE July 11, 2007 July 11, 2007

Inspire Pharmaceuticals — CEUT Emerging Growth Conference 2007 on 6ix